Essa Pharma
Investors/Media

With a focus on the development of small molecule drugs for the treatment of cancer, the goal at ESSA is to develop a pipeline of oncology therapeutics. We will continue to research innovative ideas with the goal of providing a promising future for the patients and community we serve.

With a focus on the development of small molecule drugs for the treatment of cancer, the goal at ESSA is to develop a pipeline of oncology therapeutics. We will continue to research innovative ideas with the goal of providing a promising future for the patients and community we serve.

Latest News
Oct 9, 2025
ESSA Announces Completion of Arrangement with XenoTherapeutics

ESSA Pharma Inc. (NASDAQ: EPIX) ("ESSA" or the "Company") today announced the completion of XenoTherapeutics' ("Xeno") previously announced acquisition of ESSA (the "Acquisition"). Xeno...

Oct 6, 2025
ESSA Securityholders Approve Acquisition by XenoTherapeutics

ESSA Pharma Inc. (NASDAQ: EPIX) ("ESSA" or the "Company") is pleased to announce that its Securityholders (as defined below) have approved the acquisition of all of the issued and outstanding...

Sep 30, 2025
ESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Amended Interim Order

SOUTH SAN FRANCISCO, USA AND VANCOUVER, CANADA, Sept. 30, 2025 - ESSA Pharma Inc. (“ESSA,” or the “Company”) (NASDAQ: EPIX) today announced that, in connection with its previously...

View All News

View All

Stock Performance

Last Price

Change

Volume

NASDAQEPIX
Learn More

Investor & Media Contacts

Investor Contact
Argot Partners
essa@argotpartners.com

Media Contact
Argot Partners
essa@argotpartners.com